6-K: Transaction Notification
6-K: Blenrep Shows Significant Overall Survival Benefit, Reducing the Risk of Death by 42% in Multiple Myeloma at or After First Relapse
6-K: Blenrep Combination Accepted for Priority Review in China in Relapsed/Refractory Multiple Myeloma
6-K: Us Fda Accepts Gsk's Submission for the Use of Nucala (Mepolizumab) in Copd
6-K: Gsk and Zhifei Revise and Extend Strategic Vaccine Collaboration in China
6-K: Transaction Notification
6-K: Total Voting Rights and Capital
6-K: Gsk's Fully Liquid Menveo Meningococcal Vaccine Approved by European Commission
6-K: Blenrep Combinations Accepted for Review by the Us Fda for the Treatment of Relapsed/Refractory Multiple Myeloma
6-K: Arexvy Approval Expanded to Adults Aged 50-59 at Increased Risk of Severe Rsv Disease in Japan
6-K: Transaction Notification
6-K: Linerixibat Shows Positive Phase Iii Results in Cholestatic Pruritus in Primary Biliary Cholangitis
SC 13D/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-GSK plc(9.5%)
6-K: Lenrep Shows Overall Survival Benefit in Head-to-Head Dreamm-7 Phase Iii Trial for Relapsed/Refractory Multiple Myeloma
6-K: Block Listing Six Monthly Return
SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-GSK plc(11.2%)
6-K: Transaction Notification
6-K: Gsk Publishes Provisional Dividend Dates
6-K: Total voting rights and capital
6-K: Transaction notification
No Data